Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Patent
1994-05-13
1997-09-16
Scheiner, Toni R.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
435 724, 436 63, 436 64, 436813, G01N 33574, G01N 3353
Patent
active
056679815
ABSTRACT:
The invention relates to methods and kits for diagnosing cancers arising from cells which express tyrosine phosphorylated CRKL protein, such as cells having the Philadelphia (Ph) chromosome, which includes chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL), through the detection of increased levels of phosphorylated CRKL protein or through the detection of increased CRKL gene copy or mRNA expression. The invention also relates to methods of treating such cancers.
REFERENCES:
patent: 5352660 (1994-10-01), Pawson
Huhn, et al., PNAS, vol. 84, No. 13, pp. 4408-4412, 1987.
Nichols, et al., Blood, vol. 84, No. 9, pp. 2912-2918, Nov. 1994.
Ten Hoeve, et al., Blood, vol. 84, No. 6, pp. 1731-1736, Sep. 1994.
Oda, et al., J. Biol. Chem., vol. 269, No. 37, Sep. 1994, pp. 22925-22928.
Ten Hoeve, et al., Oncogene, vol. 8, No. 9, pp. 2469-2474, Sep. 1993.
Koch, C.A., et al., "SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins", Science, 252: 668-74 (1991).
Mayer, B.J., et al., "A novel viral oncogene with structural similarity to phospholipase C", Nature, 332: 272-275 (1988).
Mayer, B.J. and Hanafusa, H., "Mutagenic analysis of the v-crk oncogene: requirement for SH2 and SH3 domains and correlation between increased cellular phosphotyrosine and transformation", J. Virol., 64: 3581-3589 (1990).
Reichman, C.T., et al., "The product of the cellular crk gene consists primarily of SH2 and SH3 regions", Cell Growth Differ., 3: 451-460 (1992).
Freed, E. and Hunter, T., "A 41-kilodalton protein is a potential substrate for the p210.sup.bcr-abl protein-tyrosine kinase in chronic myelogenous leukemia cells", Mol. Cell. Biol., 12: 1312-1323 (1992).
Naldini, L., et al., "Phosphotyrosine antibodies identify the p210.sup.c-abl tyrosine kinase and proteins phosphorylated on tyrosine in human chronic myelogenous leukemia cells", Mol. Cell. Biol., 6: 1803-1811 (1986).
ten Hoeve, J., et al., "Isolation of NotI sites from chromosome 22q11", Genomics, 18: 588-597 (1993).
Fioretos, T., et al., "CRK proto-oncogene maps to human chromosome band 17p13", Oncogene, 8: 2853-2855 (1993).
Matsuda, M., et al., "Two species of human CRK cDNA encode proteins with distinct biological activities", Mol. Cell Biol., 12:3482 (1992).
ten Hoeve J., et al., "Cellular interactions of CRKL, an SH2-SH3 adaptor protein", Cancer Res., 54 (10): 2563-2567 (May 15, 1994).
Feller, S.M., et al., "c-Abl kinase regulates the protein binding activity of c-crk" EMBO J, 13 (10): 2341-2351 (May 15, 1994).
Tanaka, S., et al., "Both the SH2 and SH3 domains of human CRK protein are required for neuronal differentiation of PC12 cells", Mol. Cell Biol., 13:4409 (1993).
Blake, T.J. and Langdon, W.Y., "A rearrangement of the c-cbl proto-oncogene in HVT 78-T lymphoma cells results in a truncated protein", Oncogene 7: 757-762 (1992).
Blake, T.J., et al., "The truncation that generated the v-cbl oncogene reveals an ability for nuclear transport, DNA binding and acute transformation", EMBO J, 12 (5) 2017-2026 (1993).
Langdon, W.Y., et al., "v-cbl, an oncogene from a dual-recombinant murine retrovirus that induces early B-lineage lymphomas", Proc. Natl. Acad. Sci., 86: 1168-1172 (1989).
Andoniou, C.E., et al., "Tumour induction by activated abl involves tyrosine phosphorylation of the product of the cbl oncogene", EMBO J, 13 (19) 4515-4523 (Oct. 1994).
Blake, T.J., et al., "The sequences of the human and mouse c-cbl proto-oncogenes show v-cbl was generated by a large truncation encompassing a proline-rich domain and a leucine zipper-like motif", Oncogene, 6: 653-657 (1991).
Donovan, J.A., et al., "The Protein Product of the c-cbl Protooncogene Is the 120-kDa Tyrosine-phosphorylated Protein in Jurkat Cells Activated via the T Cell Antigen Receptor", J. Biol. Chem., 269 (37), 22921-22924 (Sep. 1994).
Odai, H., et al., "The Proto-oncogene Product c-Cbl Becomes Tyrosine Phosphorylated by Stimulation with GM-CSF or Epo and Constitutively Binds to the SH3 Domain of Grb2/Ash in Human Hematopoietic Cells", J. Biol. Chem., 270 (18), 10800-10805 (1995).
Groffen John H.
Heisterkamp Nora C.
Hoeve Johanna Ten
Children's Hospital of Los Angeles
Scheiner Toni R.
LandOfFree
Diagnostics and treatments for cancers expressing tyrosine phosp does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnostics and treatments for cancers expressing tyrosine phosp, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnostics and treatments for cancers expressing tyrosine phosp will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-217422